Vyome Holdings

HIND

Market cap $19M

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical program. Key anticipated benefits of an orphan drug designation include 7 years of U.S. market exclusivity, up to 25% of tax credits on clinical trials conducted in the USA, exemption from FDA Prescrip.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--LICH LOI with Remus.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome VT-1953 P2 results.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting role, Dr. Bardia will guide the clinical development of Vyome's lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds (MFW), a debilitating condition in cancer patients for which approval is being targeted in 2026. “I am excited to work with Vyome team and.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings Third Quarter 2025 Earnings Release.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Annual meeting of Vyome Holdings Inc.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo, Inc., an AI startup launched at the Massachusetts Institute of Technology (“MIT”). Concurrent with this transaction, Vyome has launched a new business unit focused on using AI to tackle inflammation. This new business unit will leverage Oculo's assets to develop an AI psychiatrist trained on data from both.